Kairos Pharma aims to fight drug resistance in prostate cancer.

Oct 6, 2026, 2:19 PM ETTrialRead the original at Benzinga

Good for KAPA

Kairos Pharma reported a median 17.7 months before cancer worsened with ENV-105 plus apalutamide, versus 2 months with apalutamide alone. This supports the drug, though the result is interim and the revised trial remains unfinished.

KAPA · Kairos Pharma Ltd.

AI read · Good for KAPA

The AI's read

A longer time before cancer worsened could help Kairos move ENV-105 forward. But this is an interim result, and the company changed the patients and drug pairing in the study. The revised trial must still show whether the benefit holds, with completion aimed for late 2027.

Get alerts for KAPA

Follow Kairos Pharma Ltd. (KAPA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for KAPA

Free on the App Store and Google Play, or on the web.